Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical
aesthetic and therapeutic skin health systems, announced today that
Company management will present a corporate overview at the 29th
Annual Canaccord Adams Global Growth Conference to be held on August
11-13 at the Intercontinental Hotel in Boston, MA. The presentation will
take place at 3:00 p.m. (EDT) on Thursday, August 11, 2009.
A live webcast of the presentation will be available via the internet by
visiting the Investor Relations section of the Company's web site at www.obagi.com.
The archived presentation will be available on the web site for 30 days.
About Obagi Medical Products, Inc.
Obagi Medical Products develops and commercializes skin health products
for the dermatology, plastic surgery, and related aesthetic markets.
Using its Penetrating Therapeutics™ technologies, Obagi Medical's
products are designed to improve penetration of agents across the skin
barrier for common and visible skin conditions in adult skin including
chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The
history of Obagi's skin care product introductions is as follows: Obagi
Nu-Derm®, 1988; Obagi-C® Rx (the first and only prescription-strength
vitamin C and hydroquinone system), 2004; Obagi® Professional-C (a line
of highly stable vitamin C serums), 2005; Obagi® Condition and Enhance
for use with cosmetic procedures to enhance patient outcomes and
satisfaction, 2006; Obagi ELASTIderm™ eye treatment and Obagi
CLENZIderm® M.D. acne therapeutic systems, 2007; a formulation of Obagi
CLENZIderm® M.D. Systems for normal to dry skin, June 2007; Obagi
ELASTIderm™ Décolletage System, January 2008; SoluCLENZ Rx Gel for acne
treatment in the pharmacy channel in August 2008; and the Obagi®
Rosaclear™ System for Rosacea in January 2009. Visit www.obagi.com
for more information.
Company:
Obagi Medical Products, Inc.
Preston Romm
CFO,
EVP of Finance, Operations and Administration
562-628-1007
or
Investors:
ICR,
Inc.
Ina McGuinness/Lena Adams, 310-954-1100
